Molecular Pathobiology, Diagnosis and Therapeutics in Oral Cancer

Dear Colleagues,

Oral and oropharyngeal cancers have emerged as significant global and public health challenges. For example, the mortality from oral cancers within the past half century remains atrociously high (over 50%!), contrasting with considerable decreases in the mortality rates for cancers of the breast, colon, prostate, and melanoma within the same timeframe. This is despite technological advances on various fronts in the management of oral cancer patients, as well as the fact that the oral cavity and the population at risk are both easily accessible. Furthermore, early diagnosis has been painfully slow when compared to the enhanced early detection of cancers of the breast, colon, prostate, and melanoma. While surgery, often with significant morbidity, remains the mainstay of treatment of oral cancer patients, effective chemotherapeutic treatment continues to yield suboptimal and frustrating outcomes. In spite of increased diligence on the part of the clinicians in their examination of patients at risk, early diagnosis of oral cancer continues to be impeded and elusive because of the persistence of outdated paradigms and the lack of optimized, validated, and easily available diagnostic adjuncts.

This Special Issue seeks to provide an in-depth and reference-friendly update on the roles of known etiologic/risk factors, current clinical diagnostic tools (including the roles of recently enhanced “liquid biomarkers”), molecular pathogenic mechanisms and diagnostic biomarkers (including recently identified progression indicators), and refined management philosophies for oral cancer patients.

Enthusiastic researchers, academics and clinicians within, but not limited to, the fields of nanotechnology, molecular biology, oncology, therapeutics and diagnostic sciences are invited to submit relevant manuscripts to this Special Issue. We encourage the submission of systematic reviews, bibliometric analyses, comprehensive narrative reviews, clinical trials, clinical epidemiological studies, commentaries, letters to the editor, and other manuscript types. Thank you.

Prof. Dr. Kalu U.E. Ogbureke
Dr. Kehinde Kazeem Kanmodi
Prof. Dr. Charles Oluwaseun Adetunji
Dr. Timothy Olukunle Aladelusi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Oral is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• sibling
• diagnostic biomarkers
• prognostic biomarkers
• oral cancer management
• liquid biopsy
• epithelial–mesenchymal interactions
• epidemiology of oral cancer
• HPV-associated oral cancers